Could a lower drug dose make stem cell transplants safer for blood cancer patients?
NCT ID NCT06926595
First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 25 times
Summary
This study tests whether a lower dose of a drug called cyclophosphamide can prevent graft-versus-host disease (GVHD) after a stem cell transplant for blood cancers like leukemia. About 41 adults will receive the lower dose after transplant. The goal is to see if it works as well as higher doses but with fewer side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGIC MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Penn State Cancer Institute
RECRUITINGHershey, Pennsylvania, 17033, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.